Form 4: Vera Therapeutics Director Acquires 14,000 Stock Options
SEC Form 4 Filing
Director Scott W. Morrison acquired 14,000 stock options in Vera Therapeutics, Inc. on May 15, 2024.
Summary
- On May 15, 2024, Scott W. Morrison, a director of Vera Therapeutics, Inc., acquired 14,000 stock options.
- The exercise price of these options is $42.69.
- The options vest fully on the earlier of the first anniversary of the grant date or the date of the Company's 2025 annual stockholder meeting, contingent upon continuous service.
- The options also vest fully upon a change in control, subject to continuous service through that date.
- The expiration date for these options is May 14, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director acquiring stock options suggests confidence, but it's a routine transaction.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting of the options is tied to the director's continuous service and potentially a change in control, suggesting a long-term commitment.
Industry Context
Form 4 filings are routine disclosures of insider transactions, providing transparency to the market about the actions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | Date of transaction: Director acquired 14,000 stock options. |
| 05/14/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.